Based on the presence of anti-DSG2 autoantibodies in ARVC patients (Chatterjee et al. 2018), there has been significant effort in understanding specific immune cell populations and chemokines that drive the cardiac inflammatory response in ARVC using DSG2 models that harbor ARVC disease features and either express a mutant truncated form of DSG2 or cardiomyocyte restricted DSG2 loss (Lubos et al. 2020). The gene discussed is DSG2; the disease is Arrhythmogenic right ventricular dysplasia.